{"schema_version":"secwatch.filing_event.v1","accession":"0001680367-25-000056","form_type":"8-K","ticker":"STTK","cik":"0001680367","company_name":"Shattuck Labs, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.131962+00:00","generated_at":"2026-05-16T23:47:16.214792+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Shattuck Labs Q3 net loss $10.1M; SL-325 Phase 1 dosing underway; $103M private placement","bullets":["First participants dosed in Phase 1 trial of SL-325 (DR3 antagonist) in healthy volunteers; SAD/MAD enrollment expected Q2 2026.","Closed $103M private placement in August 2025; cash runway extended into 2029 assuming full warrant exercise.","Net loss $10.1M ($0.14/sh) vs $16.6M ($0.33/sh) in Q3 2024; R&D expenses down to $7.6M from $16.3M.","Appointed Dan Baker, M.D. and Mona Ashiya, Ph.D. to Board of Directors in August 2025.","Cash and equivalents $86.1M as of Sept 30, 2025; funding to support SL-325 through Phase 2 and other milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001680367-25-000056","json":"https://secwatch.observer/filing/0001680367-25-000056.json","markdown":"https://secwatch.observer/filing/0001680367-25-000056.md","text":"https://secwatch.observer/filing/0001680367-25-000056.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680367/000168036725000056/0001680367-25-000056-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680367/000168036725000056/sttk-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:47:16.214792+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}